 This pilot study will evaluate changes in blood and urine inositol levels half-life pharmacokinetics of multiple doses of myo-inositol provided by Abbott Laboratories, Abbott Nutrition Division given to very low birth weight infants. The premise is that maintaining inositol concentrations similar to those occurring naturally in utero will reduce the rates of retinopathy and bronchopulmonary dysplasia in premature infants. Results from this study will be used to select the dose for a large multi-center trial. 